Atlas Trials

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Clinical trial NCT06165341 · RECRUITING

Trial details

NCT number
NCT06165341
Sponsor
Takeda
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Alpha1-Antitrypsin Deficiency
Start date
2024-03-01
Primary completion
2028-08-26
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.